In the cohort of patients treated with bortezomib-based therapies, the levels of LOC606724 and SNHG1 mRNAs in MM cells were much higher in non-responders than those who responded to the treatment (Fig. 3c, d). This evidence concerns the gene SNHG1 and Miyoshi myopathy.